Continuous, Week-Long, Seconds-Resolved In Vivo Drug Measurements Performed with a Xenonucleic Acid-Employing Electrochemical, Aptamer-Based Sensor

The ability to monitor drug and biomarker concentrations in the body continuously and in real time could transform our understanding of physiology, enhance the diagnosis and monitoring of disease, and enable high-precision, truly personalized drug dosing. Toward this goal, we are developing electrochemical aptamer-based (EAB) sensors, the only real-time monitoring technology yet shown able to measure molecules as diverse as small molecule drugs to protein biomarkers in situ in the veins, brains, and peripheral tissues of live subjects. This advance notwithstanding, a significant challenge nevertheless remains: to date, degradation of their target-recognizing aptamer has limited the demonstrated, in vivo…

• NI
  National Institutes of Health

  Award: R01EB022015